Orforglipron (Foundayo) GLP-1 Pill
0 reviews
Out of stock- Average weight loss of 11.2% of body weight in clinical trials*
- Take it with or without food, at a time that suits your routine
- No injections, sharps disposal or refrigeration needed
- Feel fuller for longer, helping you manage hunger day to day
- Fast, discreet delivery
- 100% UK-based pharmacy
- Free advice and support
- We're rated 4.9 out of 5
Based on over 30,000 reviews collected on Google and Reviews.io.
Orforglipron (Foundayo): What You Need To Know
Orforglipron (Foundayo) is an oral weight loss treatment. It’s produced by Eli Lilly, the makers of Mounjaro injections.
Known under the brand name Foundayo in the US, orforglipron is designed to support weight management when used alongside a reduced-calorie diet and increased physical activity. It helps regulate appetite, making it easier to control your food intake and maintain healthier habits.
Orforglipron (Foundayo) is similar to the Wegovy pill, which is an oral GLP-1 weight loss medication.
Orforglipron, the active ingredient in Foundayo, works to help you feel fuller for longer, which may lead to reduced appetite and calorie intake. In the ATTAIN-1 clinical trials, patients using the Foundayo pill at the 17.2mg dose lost 11.2% body weight over 72 weeks.¹
While orforglipron (Foundayo) has been approved for use in the US, it’s currently awaiting approval from the Medicines and Healthcare products Regulatory Agency (MHRA) before it can be used in the UK.² Orgforglipron may be known under a different brand name if and when it becomes available in the UK.
If approved, you’ll be able to buy orforglipron (Foundayo) from UK-registered pharmacies, including The Independent Pharmacy, following an online consultation.
*Based on the 72-week ATTAIN-1 clinical trial with adults with overweight and obesity, taking orforglipron 17.2mg alongside a reduced-calorie diet and increased physical activity
Who Is Orforglipron (Foundayo) GLP-1 Pill Suitable For?
Suitable for pregnancy?No
Suitable for breastfeeding?No
Consultation required?Yes
Orforglipron (Foundayo) Summary
Orforglipron (Foundayo) GLP-1 Pill information
When Will Orforglipron (Foundayo) Be Available To Buy in the UK?
Orforglipron (Foundayo) was approved for the US in April 2026. Before you can buy orforglipron (Foundayo) in the UK, it needs to be approved by the MHRA. An approval decision is expected in late 2026, but that timeline could change.
Once approved, we expect you’ll be able to buy orforglipron (Foundayo) at UK-regulated pharmacies, including The Independent Pharmacy.
What Is Orforglipron (Foundayo)?
If you’re trying to lose weight, you might feel like you’re constantly battling hunger, cravings, or portion control. Even with the best intentions, it can be difficult to stick to a calorie deficit when your appetite feels hard to manage. Over time, this can make weight loss feel frustrating, inconsistent, and difficult to maintain.
Orforglipron (Foundayo) is a prescription weight loss treatment designed to support appetite control in adults with overweight or obesity. It belongs to the same class as drugs as Mounjaro, Ozempic and Wegovy, but it’s taken as a once-daily tablet, offering an alternative to injectable treatments.
It works by mimicking a natural hormone in the body called GLP-1, which means it mimics our natural hormones that tell us when we’re full. By acting on these signals, orforglipron may help you feel fuller sooner, stay satisfied for longer, and reduce the urge to snack or overeat.
Orforglipron (Foundayo) Vs Mounjaro Injections: Comparison
Mounjaro injections target two hormones (GLP-1 and GIP), making it generally more effective for weight loss. Orforglipron (Foundayo) is a daily pill that targets only GLP-1, so it’s easier to take but typically produces slightly less weight loss.
Feature | Foundayo Tablet | Mounjaro Injections |
Active ingredient | Orforglipron | Tirzepatide |
Type of treatment | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
How it works | Helps regulate appetite, increasing fullness and reducing hunger and food cravings | Helps regulate appetite, increasing fullness and reducing hunger and food cravings |
How often you use it | Once a day | Once a week |
Available strengths | 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
Standard starting dose | 0.8mg once a day | 2.5mg once a week |
Common side effects | Nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion | Nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion |
Weight loss in studies | 11.2% average weight loss over 72 weeks¹ | 22.5% average weight loss over 72 weeks³ |
Approved for weight loss in the UK? | No | Yes |
Orforglipron (Foundayo) Vs Wegovy Injections: Comparison
Wegovy injections (semaglutide) are weekly injections that typically produce slightly greater weight loss, while orforglipron (Foundayo) is a new daily pill that’s easier to take because there are no fasting or timing rules.
Both orforglipron (Foundayo) and Wegovy work on the same GLP-1 pathway, but Wegovy is generally more effective, whereas Foundayo may be considered more convenient and is needle-free.
Feature | Foundayo Tablet | Wegovy Injections |
Active ingredient | Orforglipron | Semaglutide |
Type of treatment | GLP-1 receptor agonist | GLP-1 receptor agonist |
How it works | Helps regulate appetite, increasing fullness and reducing hunger and food cravings | Helps regulate appetite, increasing fullness and reducing hunger and food cravings |
How often you use it | Daily | Weekly |
Available strengths | 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg | 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, 7.2mg |
Standard starting dose | 0.8mg once a day | 0.25mg once a week |
Common side effects | Nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion | Nausea, vomiting, diarrhoea, constipation, stomach pain, fatigue |
Weight loss in studies | 11.2% average weight loss over 72 weeks¹ | Wegovy 7.2mg gives 20.7% average weight loss over 72 weeks⁴ |
Approved for weight loss in the UK | No | Yes |
Orforglipron (Foundayo) Vs Wegovy Pill: Comparison
The main difference between the orforglipron (Foundayo) pill and the Wegovy pill is how they’re made. Wegovy is protein-based, while orforglipron (Foundayo) is not. This means Wegovy has to be taken on an empty stomach with water, but orforglipron (Foundayo) can be taken any time of day, with or without food or drink.
In terms of effectiveness, both treatments can lead to significant weight loss, but Wegovy has a longer track record and is generally considered slightly more effective overall, while orforglipron (Foundayo) offers greater convenience as a simpler daily pill.
Feature | Foundayo Tablet | Wegovy Pill |
Active ingredient | Orforglipron | Semaglutide |
Type of treatment | Small-molecule (non-peptide) GLP-1 receptor agonist | GLP-1 receptor agonist |
How it works | Helps regulate appetite, increasing fullness and reducing hunger and food cravings | Helps regulate appetite, increasing fullness and reducing hunger and food cravings |
How often you use it | Daily at any time, no dietary restrictions | Daily, first thing in the morning, on an empty stomach, 30 minutes before any other food or drink, with a maximum of 100ml of water |
Available strengths | 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg | 1.5mg, 4mg, 9mg, 25mg |
Standard starting dose | 0.8mg once a day | 1.5mg once a day |
Common side effects | Nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion | Nausea, vomiting, diarrhoea |
Weight loss in studies | 11.2% average weight loss over 72 weeks¹ | 15.1% average weight loss over 68 weeks⁵ |
Approved for weight loss in the UK | Not yet | Not yet |
How Does Orforglipron (Foundayo) Work?
Orforglipron (Foundayo) is a GLP-1 receptor agonist. That means it mimics a natural hormone called GLP-1 in your body, which is released after eating.
This hormone affects several things in your body:
- It reduces hunger signals in the brain so you don’t feel as hungry
- It increases feelings of fullness so you feel satisfied with smaller portions
- It slows stomach emptying, helping you feel fuller for longer
- It helps regulate blood sugar levels, which may reduce hunger signals
How To Use Orforglipron (Foundayo)
- Swallow tablets whole. Do not crush, break or chew the tablet.
- Take 1 pill a day.
- Foundayo can be taken with or without food or water.
How To Store Orforglipron (Foundayo)
- Store at room temperature at 20°C–25°C.
- Orforglipron (Foundayo) is sensitive to light. Protect orforglipron (Foundayo) from light by keeping it in the original box.
- Keep orforglipron (Foundayo) out of the reach of children.
Orforglipron (Foundayo) Effectiveness
In clinical trials, orforglipron (Foundayo) helped people with overweight or obesity lose an average of 11.2% of their body weight over 72 weeks.¹
In people with type 2 diabetes, weight loss was lower, typically around 5–10%.⁶ This is similar to what’s seen with other GLP-1 treatments.
Orforglipron (Foundayo) In Clinical Trials
Trial | Duration | Weight Loss | Key Insight |
ATTAIN-1 | 72 weeks | 11.2% | Establishes 11.2% as the expected upper bound for weight loss in patients without diabetes on oral orforglipron |
ATTAIN-2 | 72 weeks | 5-10% | Mean weight loss is lower in people with type 2 diabetes |
Orforglipron (Foundayo) Ingredients
Active ingredient: orforglipron
Other ingredients: copovidone, crospovidone, magnesium stearate, microcrystalline cellulose and sodium carbonate anhydrous.
For the most up-to-date list of ingredients, please check the Patient Information Leaflet inside the box.
Orforglipron (Foundayo) Side Effects
Like many medications, orforglipron (Foundayo) may cause side effects. These can include:
- Nausea
- Constipation
- Diarrhoea
- Vomiting
- Abdominal pain
- Fatigue
- Gastroesophageal reflux disease (GERD)
- Indigestion
Be sure to inform your prescriber of any concerns or side effects you experience.
If you do have any side effects, want to prepare for starting orforglipron or increasing your dose, our unique GLP-1 Side Effects Treatment Pack may help.
Orforglipron (Foundayo) Warnings
Please read the following warnings carefully before use.
- Do not use orforglipron (Foundayo) if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
- Do not use orforglipron (Foundayo) if you’re allergic to orforglipron or any of the other ingredients in Orforglipron (Foundayo).
- In animal studies, GLP-1 medicines have been associated with thyroid tumours. It is not known if this applies to humans. Tell your healthcare professional if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
Important: Orforglipron (Foundayo) may reduce the effectiveness of oral contraceptives. Additional barrier contraception, such as condoms, is recommended.
This treatment may not be suitable for all patients, including some older adults or those with complex health conditions.
For a full list of warnings and side effects, please see the Patient Information Leaflet.
Orforglipron (Foundayo) FAQs
When is orforglipron (Foundayo) going to be available in the UK?
Orforglipron (Foundayo) is expected to be available later this year in the UK, although timelines may change. Orforglipron (Foundayo) has been approved for use in the US, but is still awaiting UK approval by the MHRA.
Where can I buy orforglipron (Foundayo) in the UK?
Orforglipron (Foundayo) is not yet available to buy in the UK as it’s waiting on approval from the MHRA. Once approved, it’s likely to be available at regulated pharmacies, including The Independent Pharmacy.
How much will orforglipron (Foundayo) cost?
In the US, where orforglipron is sold under the brand name Foundayo, the cost varies depending on insurance and dosage.
UK pricing will be confirmed if and when the treatment is approved.
Does orforglipron (Foundayo) cost more than Mounjaro injections?
We don’t yet know how much orforglipron (Foundayo) will cost in the UK.
Final pricing will be confirmed once it’s approved and available.
What is the difference between orforglipron (Foundayo) and the Mounjaro injections?
Orforglipron (Foundayo) is a daily tablet that works on the GLP-1 pathway to reduce appetite, while Mounjaro is a weekly injection that targets both GLP-1 and GIP, making it more potent. Both help control hunger and support weight loss, but Mounjaro typically leads to greater results overall.
In studies, orforglipron (Foundayo) shows 11.2% average weight loss¹, compared to 22.5% with Mounjaro³,though orforglipron (Foundayo) offers the convenience of a daily pill without injections.
Is orforglipron (Foundayo) as effective as GLP-1 injections?
Orforglipron (Foundayo) is a more convenient option than GLP-1 injections, but is not as clinically effective as GLP-1 injections.
Foundayo Tablet
Wegovy Injection
Mounjaro Injection
Weight loss results over 72 weeks
11.2%¹
20.7%⁴
22.5%³
Who is eligible for orforglipron (Foundayo)?
If approved in the UK, orforglipron (Foundayo) may be prescribed to adults:
- With a BMI of 30 or above
- With a BMI of 27 or above and a related health condition (such as high blood pressure or type 2 diabetes)
What orforglipron (Foundayo) dosages and strengths are available?
Orforglipron (Foundayo) is available in the current strengths:
- 0.8mg
- 2.5mg
- 5.5mg
- 9mg
- 14.5mg
- 17.2mg
How do I switch from injections to orforglipron (Foundayo)?
If you wish to switch from weight loss injections to orforglipron (Foundayo), you need to do so under clinical supervision.
When orforglipron (Foundayo) becomes available, speak to our UK-registered pharmacists about making the transition safely.
What if I miss a dose of orforglipron (Foundayo)?
If you miss a dose of orforglipron (Foundayo), take the missed dose as soon as you remember. If it’s been longer than a day, skip that dose and take the next day’s dose as normal.
Is orforglipron (Foundayo) effective for weight loss in non-diabetics?
Yes, orforglipron (Foundayo) is effective for weight loss in non-diabetics. The ATTAIN-1 clinical trial demonstrated that orforglipron (Foundayo) produced an average weight loss of 11.2% in non-diabetics.¹
What happens if you take too much orforglipron (Foundayo)?
If you take more orforglipron (Foundayo) than you’ve been prescribed, you should seek medical advice as soon as possible.
If you experience severe symptoms, seek medical advice immediately.
What should I avoid while using orforglipron (Foundayo)?
Avoid eating greasy, rich or high-fat food when using orforglipron (Foundayo). It works best with a healthy balanced diet and increased physical activity.
Orforglipron key takeaways
Orforglipron (Foundayo) is a weight loss treatment that offers a convenient alternative to injections. As a once-daily tablet with no food or timing restrictions, it may suit people looking for a simpler way to manage their weight alongside a healthy diet and lifestyle.
While it has shown promising results in clinical trials, it’s not yet approved for use in the UK. Once available, it will require a prescription and clinical assessment to ensure it’s safe and suitable for you.
If you’re exploring weight loss treatment options, you can start an online consultation with our UK-registered clinicians. They’ll assess your needs and help you choose the most appropriate treatment for you.
We’re a Fully Regulated Online Pharmacy
As a UK-based pharmacy, we follow the same strict regulatory standards as any physical pharmacy. Our expert clinical team and services are overseen by multiple regulatory bodies to ensure your care is always safe, secure and confidential.
- View Our GPhC Registration
View Our CQC RegistrationCare Quality Commission (CQC)
Visit The GMC WebsiteGeneral Medical Council (GMC)
View Our NHS ListingNHS Prescriptions
Visit The NPA WebsiteNational Pharmacy Association (NPA)
View The DiCE NetworkDigital Clinical Excellence (DiCE)
Test Our LegitScript CertificationLegitScript
View Our CertificationNCSC Cyber Essentials
Search For Our ListingLiving Wage Employer
Run by experienced healthcare professionals
We think accessing healthcare should be easy. Whether we’re fulfilling NHS prescriptions or helping people find the right treatments, we aim to offer our customers dependable, economical and convenient access to medicines with a personal and discreet service.
Related Treatments
- Best seller
Mounjaro 2.5mg - 15mg Injections
Mounjaro Weight Loss Injections£179.99 - Best seller
Wegovy 0.25mg - 7.2mg Injections
Wegovy Weight Loss Injections 0.25mg - 7.2mg£104.99 - Best seller
Orlistat 120mg Capsules
Orlistat 120mg Capsules£29.89 
Alli
Alli 60mg Capsules£49.99
We stock 14 other treatments for Weight Loss
Visit our Weight Loss page for treatments, advice and FAQs.
Ordering as easy as 1, 2, 3
1. Find the ideal treatment
2. Get a free consultation
3. Enjoy speedy delivery
- References
- 1. Wharton S et al, Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
- 2. FDA Approves First New Molecular Entity Under National Priority Voucher Program
- 3. Jastrebof, Ania M, et al, Tirzepatide Once Weekly for the Treatment of Obesity
- 4. Wharton S, et al, Once-weekly semaglutide 7.2mg in adults with obesity (STEP UP)
- 5. Knop FK, et al. Oral semaglutide 50mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
- 6. Prof Horn et all, Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial